Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

PMID:
30115664
2.

Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.

Basit F, van Oppen LM, Schöckel L, Bossenbroek HM, van Emst-de Vries SE, Hermeling JC, Grefte S, Kopitz C, Heroult M, Hgm Willems P, Koopman WJ.

Cell Death Dis. 2017 Mar 30;8(3):e2716. doi: 10.1038/cddis.2017.133.

3.

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.

Willuda J, Linden L, Lerchen HG, Kopitz C, Stelte-Ludwig B, Pena C, Lange C, Golfier S, Kneip C, Carrigan PE, Mclean K, Schuhmacher J, von Ahsen O, Müller J, Dittmer F, Beier R, El Sheikh S, Tebbe J, Leder G, Apeler H, Jautelat R, Ziegelbauer K, Kreft B.

Mol Cancer Ther. 2017 May;16(5):893-904. doi: 10.1158/1535-7163.MCT-16-0474. Epub 2017 Mar 14.

4.

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B.

Cancer Res. 2016 Nov 1;76(21):6331-6339. Epub 2016 Aug 19.

5.

Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth.

Schöckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, Algire C, Hägebarth A, Willems PH, Kopitz C, Koopman WJ, Héroult M.

Cancer Metab. 2015 Oct 20;3:11. doi: 10.1186/s40170-015-0138-0. eCollection 2015.

6.

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.

Meier JC, Haendler B, Seidel H, Groth P, Adams R, Ziegelbauer K, Kreft B, Beckmann G, Sommer A, Kopitz C.

Cancer Med. 2015 Feb;4(2):253-67. doi: 10.1002/cam4.354. Epub 2014 Dec 10.

7.

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Müller-Tiemann B, Kreft B, Ziegelbauer K.

Mol Cancer Ther. 2014 Jun;13(6):1537-48. doi: 10.1158/1535-7163.MCT-13-0926. Epub 2014 Apr 8.

8.

Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.

Grismayer B, Sato S, Kopitz C, Ries C, Soelch S, Schmitt M, Baretton G, Krüger A, Luther T, Kotzsch M, Magdolen V.

Biol Chem. 2012 Dec;393(12):1449-55.

PMID:
23667902
9.

Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.

Petrul HM, Schatz CA, Kopitz CC, Adnane L, McCabe TJ, Trail P, Ha S, Chang YS, Voznesensky A, Ranges G, Tamburini PP.

Mol Cancer Ther. 2012 Feb;11(2):340-9. doi: 10.1158/1535-7163.MCT-11-0523. Epub 2011 Dec 6.

10.

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.

Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, Schmitt M, Luther T, Kotzsch M, Krüger A, Magdolen V.

Breast Cancer Res Treat. 2011 Jun;127(3):649-57. doi: 10.1007/s10549-010-1042-5. Epub 2010 Jul 16.

PMID:
20635136
11.

Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.

Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gänsbacher B, Krüger A.

J Cell Mol Med. 2010 Dec;14(12):2760-70. doi: 10.1111/j.1582-4934.2009.00951.x.

12.

Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver.

Kopitz C, Gerg M, Gansbacher B, Krüger A.

Hum Gene Ther. 2008 Oct;19(10):1039-49. doi: 10.1089/hum.2008.078.

PMID:
18681831
13.

Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases.

Gerg M, Kopitz C, Schaten S, Tschukes A, Kahlert C, Stangl M, von Weyhern CW, Brücher BL, Edwards DR, Brand K, Krüger A.

Mol Cancer Res. 2008 Mar;6(3):341-51. doi: 10.1158/1541-7786.MCR-07-2032.

14.

Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, von Weyhern CW, Brücher BL, Brand K, Coussens LM, Edwards DR, Krüger A.

Cancer Res. 2007 Sep 15;67(18):8615-23.

15.
16.

Antimetastatic activity of a novel mechanism-based gelatinase inhibitor.

Krüger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S, Fridman R.

Cancer Res. 2005 May 1;65(9):3523-6.

17.

Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis.

Elezkurtaj S, Kopitz C, Baker AH, Perez-Cantó A, Arlt MJ, Khokha R, Gansbacher B, Anton M, Brand K, Krüger A.

J Gene Med. 2004 Nov;6(11):1228-37.

PMID:
15390257
18.

Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors.

Banke IJ, Arlt MJ, Pennington C, Kopitz C, Steinmetzer T, Schweinitz A, Gansbacher B, Quigley JP, Edwards DR, Stürzebecher J, Krüger A.

Biol Chem. 2003 Oct-Nov;384(10-11):1515-25.

PMID:
14669995
19.

Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.

Krol J, Kopitz C, Kirschenhofer A, Schmitt M, Magdolen U, Krüger A, Magdolen V.

Biol Chem. 2003 Jul;384(7):1097-102.

PMID:
12956426
20.

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.

Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V.

Curr Pharm Des. 2003;9(19):1529-43. Review.

PMID:
12871066
21.

Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model.

Arlt M, Kopitz C, Pennington C, Watson KL, Krell HW, Bode W, Gansbacher B, Khokha R, Edwards DR, Krüger A.

Cancer Res. 2002 Oct 1;62(19):5543-50.

22.

High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.

Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Krüger A, Magdolen V.

FEBS Lett. 2002 Sep 25;528(1-3):212-6.

23.

Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.

Krüger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gänsbacher B, Schmitt M.

Cancer Res. 2001 Feb 15;61(4):1272-5.

Supplemental Content

Loading ...
Support Center